Efficacy and safety of Sultamicillin (Ampicillin/Sulbactan) and Amoxicillin/Clavulanic Acid in the treatment of upper respiratory tract infections in adults: an open-label, multicentric, randomized trial by Ferreira, João Batista et al.
104
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 72 (1) JANUARY/FEBRUARY 2006
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
Efficacy and safety of 
Sultamicillin (Ampicillin/
Sulbactan) and Amoxicillin/
Clavulanic Acid in the 
treatment of upper respiratory 
tract infections in adults - 
an open-label, multicentric, 
randomized trial
   Summary
João Batista Ferreira1, Priscila Bogar Rapoport2, 
Eulália Sakano3, Arthur Octávio De Ávila Kós4, 
Otávio B. Piltcher5, Shirley Shizue Nagata 
Pignatari6, Sebastião Diógenes Pinheiro7, Marcos 
Mocellin8
1 Assistant Professor, Head of the Otolaryngology Department – Surgery Department – Medical School of the UFG.
2 PhD in Otolaryngology by the Medical School of the USP, Full Professor of Otolaryngology of the Medical School of the ABC.
3 Head of the Rhinology Department of the Otolaryngology Service of the UNICAMP.
4 Associate Professor of Otolaryngology by the Universidade Federal do Rio de Janeiro.  Full Professor of the Federal University of Rio de Janeiro.
5 Physician hired by the Otolaryngology Department of the University Hospital of Porto Alegre - RS.
6 Assistant Professor of the Otolaryngology and Head and Neck Department - UNIFESP / EPM.
7 PhD in Medicine.  Physician from the University of the Walter Cantídio Hospital of the Medical School of Ceará.
8 MSc and PhD from the Paulista School of Medicine – SP. Full Professor of the Otolaryngology
Department of the University of Paraná.
Medical School of the Federal University of Goiás.
Mailing address: João Batista Ferreira - a/c Aline Guerra Rua Ministro Gastão Mesquita 515 ap. 112 Pompéia São Paulo SP 05012-010
Tel (0xx11) 9404-2344 - E-mail: algmnp@uol.com.br
Paper submitted to the ABORL-CCF SGP (Management Publications System) on April 5th, 2005 and accepted on May 24th, 2005.
Upper respiratory tract infections are the most common 
causes of medical visits in children and adults, demanding 
massive use of antibiotics. Bacterial resistance caused by beta-
lactamase is one of the most serious problems in this matter. 
Sultamicillin, a double pro-drug of Ampicillin/Sulbactan, 
is a potent beta-lactamase inhibitor which can face this 
challenge. Aim: evaluate efficacy, safety and tolerability of 
Ampicillin/Sulbactan compared to Amoxicillin/Clavulanate 
in upper respiratory tract infections in adults. Methods: 
102 patients were enrolled and randomized to receive 
Ampicillin/Sulbactan or Amoxicillin/Clavulanate during 10 
days. They were evaluated 10 and 30 days after treatment to 
learn about the therapeutic response. Results: There were 
no differences between the two groups respecting cure at 
the end of treatment (visit 2) or at the end of the study (visit 
3). Cure ratio was 61.7% and 93.2% (visits 2 and 3) in the 
Amoxicillin/Clavulanate group compared to 64.4% and 97.4%, 
respectively, in Ampicillin/Sulbactan group. The adverse 
events ratio for the two groups was the same (p=0.940). The 
number of patients with diarrhea was greater in the group 
of patients receiving Amoxicillin/Clavulanate (70.6%) than in 
the group receiving Ampicillin/Sulbactan (29.4%) (p=0.0164). 
Conclusions: Ampicillin/Sulbactan is as safe and efficient 
as Amoxicillin/Clavulanate in the empiric treatment of upper 
respiratory infections in adults. The low occurrence of 
diarrhea in the group receiving Ampicillin/Sulbactan needs 
confirmation in other studies.
Key words: ampicillin, sulbactan, amoxicillin, clavulanic, in-
fections, upper respiratory tract.
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INTRODUCTION
Upper airway infections in children and adults are 
the most common diseases, and also the most common 
reasons for seeking medical consult in primary care. They 
also constitute the major diagnosis that require the use of 
antibiotics. Its diagnosis and treatment have an impact not 
only from the stand point of population health, but also 
from the social and economical stand point, because of 
the cost of medical care, cost of antibiotic used and for the 
loss they represent as far as work and school absenteeism 
are concerned. Taking Acute Otitis Media in children for 
instance, American data points towards a total of 16 million 
visits on this account in the year 2000. These visits gener-
ate a total 13 million prescriptions, meaning 802 antibiotic 
prescribed for each group of 1,000 visits. The cost of each 
antibiotic therapy varied from US$ 10 to US$ 100.
The proper use of antibiotics not only in a hospital 
setting, but also in handling the most common infections in 
the community, has been the objective of ever increasing 
debates, in an attempt to contain the growing resistance 
rates that have been seen. Great emphasis have been 
given to standardizations published by national entities 
and universities, where evidence based approach reviews 
the major points related to the diagnosis and treatment of 
infections. Many standardizations have been recently pub-
lished about otitis, sinusitis and pharyngo-tonsillitis2-5.
The major discussions in these documents are fo-
cused on whether or not it is necessary to use antibiotics 
in AURTI (acute upper respiratory tract infections) and, 
specially in non-complicated Acute Otitis Media (AOM). 
The recommendation of initial use of symptomatic medica-
tion followed by antibiotics if there is no clinical improve-
ment with the patient, is based on the high incidence of 
viral etiology in these pathologies. Notwithstanding, it can 
not be followed in many cases when the decision has to 
be made quickly, without the possibility of having the 
patient return, as is the case of ER visits. For this reason, 
great emphasis should be given to aspects that support 
the most accurate possible diagnosis. And, from then, the 
choice of antibiotic2,3,5.
As far as diagnosis is concerned, there is some con-
sensus: history of acute onset of symptoms; presence of 
exudation/inflammation signs in the middle ear, choanae 
and nasal cavities or throat; pain, satellite lymph node 
involvement and fever.
The difficulties lie on the real possibility of estab-
lishing reliable and reproductive parameters to establish 
the presence of inflammatory and/or exudative clinical 
signs. The different clinical experiences and the available 
technology translate themselves into different diagnostic 
approaches in about 50% of the non-complicated cases. 
Particularly in pharyngo-tonsillitis, the germ culture and 
the quick strep test are recommended, however they are 
difficult to have in our settings6-9.
AURTI etiology rests on the knowledge of the 
habitual flora in the upper airways and the rarely iso-
lated prevalent micro-organisms. In pharyngo-tonsillitis 
the prevalent bacterial agent is the group A hemolytic β 
streptococcus. In AOM and sinusitis the prevalent micro-
organisms are Streptococcus pneumonia, Haemophilus 
influenza and Moraxella catarhalis.
The choice of the antimicrobial agent should be 
guided by this knowledge. For clinicians and pediatricians, 
the choice of antimicrobial agent is a key issue. Right now 
the attention of the medical community and the general 
public is directed towards the high cost of medication 
and the growing rates of antibiotic resistance10. Therefore, 
judicious choice of antimicrobial agents is becoming a 
priority.
Ampicillin/Sulbactan is a combination of antibiotics 
made up of ampicillin, a betalactam and sulbactam, a beta-
lactamase inhibitor11. By adding sulbactan we consider-
ably broaden the ampicillin action spectrum, including B 
fragilis, Klebsiella sp, S aureus (MS) and H influenza.
The betalactam core destruction of penicillin and 
cephalosporin by bacterial b-lactamase, constitutes the 
clinical most important mechanism of bacterial resistance 
against these antibiotics. The lack of receptor binding may 
be caused by: (1) changes in the permeability of the cell 
membrane and/or (2) changes in target site biding capacity 
and (3) enzymatic destruction by antibiotics.
The third of these three main causes is the most 
frequent origin of antibiotic inefficacy. Beta-lactamase 
production causing bacterial resistance is one of the most 
severe problems of clinical practice today. B-lactamase may 
be produced either by gram positive or by gram negative 
bacteria. They destroy the antibiotic Betalactam core, turn-
ing them useless. This destruction occurs by the hydrolysis 
of the amide bond in the betalactam ring, resulting in the 
production of acid derivatives that do not have antibacte-
rial properties. Clinical failure appears when a sufficient 
number of antibiotic molecules is neutralized12,13.
Unasynâ (sultamicillin) is an antibiotic developed 
specifically to face these problems14,15. It is an ampicilin 
and sulbactam double pro-drug, a powerful beta-lactamase 
inhibitor. The ampicillin/sulbactam mechanism of action 
depends mainly on the sulbactam bond, a suicide inhibitor, 
with a large number of b-lactamase molecules. Sulbactam 
hydrolyzed fragments remain irreversibly bound to this 
enzyme, thus forming an inactive complex.
Ampicillin/Sulbactam pharmacokinetic studies have 
shown that the inactive pro-drug is well absorbed in the 
intestine. Ampicillin/Sulbactam is hydrolyzed in two com-
pounds in the intestine wall, sulbactam and ampicillin. The 
total ampicillin distributed is approximately twice larger 
when compared to the oral distribution of ampicillin alone. 
The high serum level achieved is followed by optimum 
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ampicillin and sulbactam tissue penetration. And finally, 
the clearance route for both active drugs is the urine16-18.
The Ampicillin/Sulbactam action spectrum en-
compasses gram positive coccus and rods, aerobic gram 
negative and some anaerobes, namely:
Peptococcus and Peptostreptococcus spp, anaer-
obes, Group B Streptococcus, Enterococcus faecalis, 
Streptococcus pneumoniae, Streptococcus pyogenes, 
Streptococcus viridans (alpha-hemolytic), C diphtheriae, 
Clostridium spp (Cl tetani, Cl perfringens, Cl botulinum), 
Listeria monocytogenes, Haemophilus influenza, E coli 
(over 50% of the strains may be resistant), P mirabilis, 
Salmonella spp (S typhimurium may be 30% to 40% resist-
ant), Shigella flexneri, Fusobacterium spp.
The Ampicillin-Sulbactam combination (Sultamicil-
lin) shows marked synergy. The MIC of many ampicillin-
resistant pathogens is reduced, being very similar to those 
sensitive organisms of the same species. The ampicillin 
activity against sensitive organisms remains the same19,20.
On the other hand, the production of significant 
quantities of b-lactamase have been associated to ce-
phalosporin resistance (Cephoxytin is the most powerful 
resistance inducer) and to the ureidopenicillins. Incubation 
with sub lethal concentrations of sulbactam clavulanic 
acid and numerous betalactam antibiotics has shown that 
sulbactam did not induce measurable levels of chromo-
some betalactam, while clavulanic acid induced 30% in 
all the strains studied.
Therefore, clavulanic acid may cause significant 
induction. This fact is in agreement with the results of an 
in vitro study on the negative R factor of the carbenicillin-
resistant P. aeruginosa strains which suggests the existence 
of an antagonism between the clavulanic acid and azlocillin 
combination, while adding sulbactam does not seem to 
affect the penicillin minimum inhibitory concentrations. So 
far, no antagonism between sulbactan and other betalactam 
antibiotics has been observed21-23.
The objective of this trial was to assess Sultamicil-
lin efficacy, safety and tolerability compared to that of 
Amoxicillin/Clavulanic acid, in the treatment of community 
acquired infections of the upper respiratory tract, specially 
otitis, sinusitis and pharyngo-tonsillitis.
METHODS
Eight Brazilian research centers participated in this 
study, recruiting 102 patients from March 22, 2002 to July 
04, 2003. The protocol design established a comparative, 
multicentric, open and randomized trial of Ampicillin/Sul-
bactan compared to Amoxicillin/Clavulanic acid. Patients 
were given 375mg bid PO Ampicillin/Sulbactan or 500mg 
tid PO Amoxicillin/Clavulanic acid after randomization. 
The study included 3 medical visits and lasted 34 days, 
having one initial visit (V-1), followed by a treatment pe-
riod of 10 consecutive days, and 2 later follow up visits 
between days 10 and 13 (V-2 – end of treatment) and 
between days 26 and 34 (V-3 – end of trial).
On visit 1, male and female patients older than 12 
years and weighing 30 Kg and more were diagnosed as car-
riers of bacterial infections in the ears, nose and/or throat, 
concomitant or not, through clinical history and physical 
exam data. Inclusion criteria were defined as follows:
• Having at least 3 of the following signs/symptoms 
for sinusitis patients: bi-phased disease, defined as the 
presence of two phases of the current disease; purulent 
anterior or posterior rhinorrhea; purulent secretion in the 
nasal cavity; facial/maxillary or teeth pain; OR
• Having at least 3 of the following signs/symp-
toms for otitis patients: local pain, fever of 38°C or more; 
otoscopy findings such as tympanic hyperemia; tympanic 
bulging; purulent or mucous-purulent secretion in the 
middle ear; OR
• Having at least 4 of the following signs/symptoms 
for pharyngo-tonsillitis patients: sudden onset, intense pain 
on swallowing; tonsillar enlargement; tonsillar hyperemia; 
exudate on the tonsils; painful anterior cervical lymph 
node disease; fever of 38°C or more.
Patients were excluded when mentioned: hypersen-
sitivity to the trial drugs or to the betalactamic; pregnancy, 
breast feeding or pregnancy possibility during the trial; 
specific systemic disease or other medical conditions, 
including viral and urinary infections and meningitis that 
could interfere in the therapeutic response assessment, in 
the absorption of medications, or safety of the trial drug; 
treatment with any systemic antibacterial drug within 14 
days before the randomization; concomitant participation 
in any other investigational drug clinical trial; blood dona-
tion or blood derivatives for transfusion in the 30 days prior 
to the treatment with the trial drugs at any time during 
the trial or after 30 days of the trial end; treatment with 
halopurinol, metrotrexate, probenecide and disulfiram, 
or other medications that may interfere on the trial drug 
assessment, and, transaminase values (ALT/SGPT or AST/
SGOT) above 3 fold the upper limit of normality (ULN), 
and serum creatinin above 2 times the ULN.
On visits 1, 2 and 3, the patients underwent a ma-
terial collection for safety exams (Complete blood count, 
biochemistry and pregnancy test, when indicated) and 
general clinical evaluation. Besides all of this, the patients 
underwent specific evaluation for signs and symptoms 
related to upper respiratory tract infections, which include 
the same aspects used to confirm the diagnosis. 
Evaluation of the clinical response
Efficacy was evaluated based on the clinical re-
sponse seen on visits 2 and 3 classified by the investigator 
according to the following criteria:
Cure: absence of all signs and symptoms of the 
disease being studied, described in the inclusion criteria 
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session.
Improvement: presence of at least one of the studied 
disease signs and symptoms described in the inclusion 
criteria, without the need to prescribe another antibiotic 
agent.
Failure: Persistence of one or more signs or symp-
toms of the studied disease described in the inclusion 
criteria, or the appearance of new signs and symptoms 
of the studied disease and/or the need to add another 
antibiotic agent or to change the study therapy.
Safety
All adverse events seen or reported were registered 
with specifications of the date of onset, the duration, the 
severity, the evolution and the possible relation with the 
trial drug. Altered findings in the lab exams were also 
reported as adverse effects.
Statistical analysis
The safety population was formed by 97 patients 
that took at least one dose of the trial medication. The 
ITT (intention to treat) efficacy population was made up 
by the patients who were given at least one dose of the 
assigned treatment and had at least one subsequent clas-
sification of clinical response to the instituted therapy. 
In other words, it was made up of 92 patients: all the 97 
safety population patients minus the 5 patients who had 
unknown clinical response on visits 2 and 3. The efficacy 
PP population is made up of the patients who received 
at least 6 doses of the assigned treatment and had at least 
one subsequent clinical response to therapy classification. 
In this study, population PP is formed by the same ITT 
population patients, because all had at least 6 doses of 
the prescribed medication.
For clinical response we created a confidence inter-
val of 95% for the difference in cure and cure + improve-
ment ratio among the treatment modalities. In order to 
compare the average of vital signs along the visits we used 
the Variance Analysis with Repeated Measures, using the 
non-structured co-variance matrix in order to model the 
existing correlation among the visits of a same patient. This 
technique takes into account the incomplete observations 
and, therefore, does not rule out the patient as a whole if 
he/she does not have all the observations in all the visits. 
All the aforementioned analysis require data normality as-
sumption which was verified and confirmed in all cases. 
Statistical analysis was made by the SAS version 8 software. 
The adopted significance level was of 0.05.
RESULTS
Patient traits
Eight Brazilian centers recruited 102 patients for the 
trial. Of these, ninety seven started the trial and received 
at least one dose of the medication. Only 83 patients 
completed the 30 days of the trial. The reasons why 14 
patients were taken off the trial are as follows: adverse 
events - 5 patients; removal from the post-informed consent 
- 3 patients; loss of follow up - 3 patients; and protocol 
violation - 2 patients. Patient 107 was taken off because 
he did not return for visit 3.
Table 1 depicts the traits of the 97 security popula-
tion patients at the trial onset. There was no statistically 
significant difference among the demographic and clinical 
traits of the patients belonging to the two groups.
The infection time, in other words, the time span 
between symptoms onset and diagnosis also did not show 
significant difference between the groups, varying from 1 
to 40 days with a 4 day median in both groups (Table 1). 
The type of infection presented by patients varied in both 
groups, although it was not significant. The Amoxicillin/
Clavulanic acid group had a greater incidence of sinusitis 
and otitis whilst the Ampicilin/Sulbactan group patients 
had a larger number of pharyngo-tonsillitis.
Table 2 lists the signs and symptoms that were part 
of diagnostic criteria for each type of infection. Table 3 
depicts signs and symptoms of patients along the trial, 
that is, at diagnosis – visit 1 – and their development in 
visits 2 and 3.
 Efficacy and clinical answer
There were no evidences of differences between 
the two groups in regards to the proportion of patients 
who did not show cure at treatment end (visit 2) or at 
trial end (visit 3). In the Amoxicillin/Clavulanic acid 
group, cure rates were 61.7% and 93.2% on visits 2 and 
3, respectively . In the Ampicilin/Sulbactan group, cure 
rates were 64.4% and 97.4%, respectively. Table 4 depicts 
Confidence intervals for the difference among cure ratios 
for both groups, as well as the results of the Fisher exact 
test. Four patients had treatment failure on the third visit 
after having reported cure on the second visit. Of these, 
3 were from the Amoxicillin/Clavulanic acid and 1 from 
the Ampicillin/Sulbactan treated group. 
Adverse Effects
There were 56 adverse effects along the trial (30 
in the Amoxicillin/Clavulanic acid group and 26 in the 
Ampicillin/Sulbactan group). The total number of patients 
who had adverse effects was 34, representing 35% of the 
total number of participants in the trial. Of these, 17 be-
longed to the Amoxicillin-Clavulanic acid group and 17 to 
the Ampicillin/Sulbactan group. The ratio of patients who 
experience at least one adverse effect was similar in both 
groups (p = 0.940). Notwithstanding, among the 34 patients 
who had adverse effects, the ratio of patients with diarrhea 
was significant higher in the Amoxicillin-Clavulanic acid 
group (70.6%) when compared to the Ampicilin/Sulbactan 
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Characteristic
Amoxicillin/Clavulanic acid Ampicillin/Sulbactan
N % N %
Age 49 100,0 48 100,0
<18 years 7 14,3 6 12,5
18-44 years 33 67,3 37 77,0
45-64 years 8 16,4 5 10,5
>65 years 1 2 0 0
Race 49 100,0 48 100,0
White 39 79,6 41 85,4
Black 8 16,3 4 8,3
Yellow 2 4,1 2 4,2
Mixed races 0 0 1 2,1
Gender 49 100,0 48 100,0
Male 19 38,8 18 37,5
Female 30 61,2 30 62,5
Time of infection (days) 49 100,0 48 100,0
1 a 2 days 9 18.4 13 27.0
3 a 5 days 25 51.0 20 41.7
6 a 10 days 7 14.3 9 18.7
> 10 days 8 16.3 6 12.6
Table 1. Patient characteristics in the beginning of the study: age, gender and race.
Type of infection and symptoms at diagnosis Treatment Group
Sinusitis 
Amoxicillin/Clavulanic acid (N=20) Ampicillin/Sulbactan (N=16)
N % N %
Bi-phased disease 13 65.00 9 56.25
Purulent anterior or posterior rhinorrhea 20 100.00 16 100.00
Purulent secretion in nasal cavities 20 100.00 15 93.75
Facial, maxillary and teeth pain 16 80.00 16 100.00
Otitis
Amoxicillin/Clavulanic acid (N=9) Ampicillin/Sulbactan (N=5)
N % N %
Local pain 9 100.00 5 100.00
Fever > 38º C 7 77.78 4 80.00
Tympanic membrane hyperemia 9 100.00 5 100.00
Bulging of the tympanic membrane 7 77.78 4 80.00
Mucus-purulent secretion in the middle year 7 77.78 2 40.00
Pharyngo-tonsillitis
Amoxicillin/Clavulanic acid (N=20) Ampicillin/Sulbactan (N=26)
N % N %
Sudden onset, intense swallowing pain 19 95.00 24 92.31
Tonsil enlargement 19 95.00 21 80.77
Tonsil hyperemia 20 100.00 26 100.00
Presence of tonsil exudate 20 100.00 25 96.15
Anterior painful neck lymph node disease 18 90.00 22 84.62
Fever > 38º C 15 75.00 20 76.92
Table 2. Type of infection; and signs and symptoms at diagnosis
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Amoxicillin-clavulanic acid Ampicillin/Sulbactan
Sign/Symptom V1 V2 V3 V1 V2 V3
Headache 59 9 0 81 2 14
Irritability 31 6 3 38 0 2
Lethargy 41 6 0 60 2 5
Post-nasal drip 37 6 0 42 0 18
Purulent rhinorrhea 43 4 0 38 0 9
Nasal mucosa edema 53 23 8 48 2 23
Obstructive nasal secretion, epistaxis, cacosmia 37 4 0 35 0 2
Fontal and maxillary sinuses tenderness 41 2 0 38 2 7
Ear pain 24 4 0 29 2 2
Hyperemic or bulged tympanic membrane 20 6 0 17 5 0
Middle year mucous-purulent secretion 33 15 0 5 11 0
Swallowing pain 51 2 0 67 0 0
Pharynx hyperemia or edema 57 11 3 75 0 9
Tonsillar exudate 41 2 0 54 0 2
Painful anterior neck lymph node disease 64 16 0 77 0 7
Fever 63 4 0 65 0 0
Cough 35 4 0 46 2 11
Halitosis 45 9 3 67 0 11
Others 61 19 2 47 23 0
Table 3. Proportions (%) of patients who presented one of the following signs/symptoms along the study, according to treatment group
V1: Visit 1 – Study onset
V2: Visit 2 – Treatment end
V3: Visit 3 – Trial end
Cure ratio
Amoxicillin/Clavulanic 
acid
Ampicillin/Sulbactan Difference(Sult - Amox) 95% CI for the difference Exact Fisher Test
Visit 2 61.70 64.44 2.74 [ -16.97; 22.46 ] P=0.9327
Visit 3 93.18 97.44 4.26 [ -4.69; 13.20 ] P=0.6185
Table 4. Ratio of cured patients at treatment end (V2) and at trial end (V3).
Type of adverse effect Amoxicillin/Clavulanic acid Ampicillin/Sulbactan
Abdominal pain 1 2
Epigastric pain 1 0
Anemia 1 1
Elevated TGO 0 1
Elevated Creatinin 1 0
Diarrhea 12 4
Dysphonia 0 1
Borborygmy 1 1
Irritability 0 1
Nausea 1 2
Sinusitis 0 1
Vaginal candidiasis 1 0
Vomit 2 0
Table 5. Adverse effect of which causality was not ruled out by the investigator.
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(29.4%) group, with p = 0.0164.
As to laboratory work up, no relevant alterations 
were found after the use of trial medications. The altered 
values were already present on visit 1 for both groups.
According to protocol criteria, there was no severe 
adverse effect. Only 5 patients were removed from the trial 
because of adverse events (2 on the Ampicillin/Sulbactan 
group and 3 on the Amoxicillin-Clavulanic acid group). 
The 9 adverse effects of these 5 patients were: diarrhea 
– 3 Amoxicillin-Clavulanic acid related events and one 
Ampicilin/Sulbactan-related event; lethargy – 1 Amoxi-
cillin-Clavulanic-acid-related event; irritability – 1 case; 
worsening of tonsillitis – 1 case; worsening of sinusitis 
– 1 case; and abdominal pain – 1 case. Bellow we listed 
the adverse effects with cause related to the drugs used. 5 
Ampicillin/Sulbactan group patients had diarrhea, however 
only 4 are listed here because the investigator considered 
that one was not related to the trial drug. 
Concomitant medication
Sixty patients (61.8%) received at least one concomi-
tant medication. Of these, 29 belonged to the Amoxicillin/
Clavulanic acid group and 31 to the Ampicillin/Sulbactan 
group. Among the drugs used, the most frequent were 
Dipirone and paracetamol, and there was no difference 
in its use among the two treatment groups. 
DISCUSSION
The results of this trial show the comparable effi-
cacy of Ampicillin/Sulbactan and Amoxicillin/Clavulanic 
acid combinations in the treatment of acute upper res-
piratory tract infections in adults. Such results correlate 
to literature reports on the use of Ampicillin/Sulbactan 
combination in the treatment of both upper and lower 
airway infections24-26.
There was no significant difference in the propor-
tion of patients who were cured at the end of treatment 
and at the end of trial in both groups. In the Ampicillin/
Sulbactan group, the cure ratios increased from 64.4%, at 
treatment end, to 97.4% by trial end. These results lead 
us to conclude that, although we are facing empirical 
treatment, because we do not know the true AURTI etiol-
ogy, Ampicillin/Sulbactan is one efficacious drug against 
the major bacteria that cause these infections in man. On 
the other hand, as far as diagnosis is concerned, the trial 
design allowed us to check the accuracy of the adopted 
criteria which are very similar to the signs and symptoms 
observed on clinical visits 2 and 3.
Similar studies were carried out comparing the 
efficacy of Ampicillin/Sulbactan and 2nd generation Ce-
phalosporin – Cephoxytin and Cefuroxim in in-patients 
with pneumonias27,28. In both groups, the results are 
comparable as far as efficacy and safety are concerned. 
In all these trials, clinical cure walked hand-in-hand with 
the bacteriological cure and S pneumoniae was the most 
frequently found micro-organism. Other trials show the 
comparative performance of Sultamicillin with amoxicil-
lin alone or in combination with Clavulanic Acid in lower 
respiratory tract infections. The clinical response was, once 
again, comparable with efficacy rates varying between 84% 
and 94%29. Considering the treatment of otitis in children, 
Ampicillin/Sulbactan proved to be efficient, with cure 
rates above those seen with the use of Cefaclor24. From 
the safety stand point, our study confirms literature reports 
that Ampicillin/Sulbactan is a well tolerated drug. There 
were no severe adverse effects, and in those that really 
happened, both groups had similar distribution. Only 
diarrhea was significantly higher in the Amoxicillin/Cla-
vulanic acid group (p=0.016). Gastrointestinal symptoms 
seem to be the most frequent adverse effect related to 
the use of Ampicillin/Sulbactan. In the same way, these 
symptoms and, diarrhea most specifically, are very com-
mon with the use of Amoxicillin/Clavulanic acid, making 
its use rather difficult sometimes, specially by children. 
In some measure, our data may have pointed towards a 
greater tolerability of Ampicillin/Sulbactan in comparison 
to Amoxicillin/Clavulanic acid, according to what has been 
reported in the literature30. Other studies must follow in 
order to investigate these aspects, with more cases and 
different populations.
In short, we have concluded that Ampicilin/Sul-
bactan is as efficient and safe as Amoxicillin/Clavulanic 
acid in the empirical treatment of adult acute upper res-
piratory tract infections, thus representing an important 
therapeutic alternative. This lower occurrence of diarrhea 
in the Ampicillin/Sulbactan group that has been observed 
requires further investigations.
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